Articles related to BIOMARKERS

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.

Physicians, take note: as scientific understanding of the genetics of aging deepens, potential interventions for age-related diseases may be on the horizon. Keep abreast of this promising field to better guide your patients towards healthy aging.

This is a golden opportunity to bolster your understanding of AML, implement novel diagnostic strategies, and integrate state-of-the-art treatment plans into your practice. Enrich your professional knowledge, earn valuable CME credits, and most importantly, help improve the lives of your patients.

Explore how the persistence of detectable Epstein-Barr virus DNA can serve as a significant predictive marker for nasopharyngeal cancer, potentially revolutionizing early diagnosis and improving survival rates.

Unveiling fresh perspectives on dry eye disease treatment through a comprehensive study that scrutinizes tear proteomic analysis and clinical parameters. In a breakthrough study on dry eye disease (DED) treatment, researchers employed tear proteomic analysis to identify potential tear biomarkers. They combined this with a rigorous examination of clinical parameters. Data was gathered from a double-blinded, national multicenter clinical trial involving 80 DED patients. The subjects underwent treatment with either 0.1% cyclosporine, 0.05% cyclosporine, or 3% diquafosol eye drops. Observations took place at four-week intervals, lasting for 12 weeks. Key metrics observed included tear break-up time, corneal erosion, conjunctival erosion, and symptom assessment in dry eye scores. This data was then correlated with protein expressions identified through the proteomic analysis. Interestingly, the same seven proteins were identified in all treatment groups. These proteins were noted to be downregulated following treatment. At the 12-week mark, all clinical parameters demonstrated a significant improvement from the baseline. However, among the groups, no significant differences in values were recorded, except in the case of corneal erosion. The latter parameter significantly improved after treatment with both cyclosporine concentrations, as compared to the diquafosol group. However, the correlation of these proteins with the clinical parameters was […]